Procter & Gamble Health Ltd

Procter & Gamble Health Ltd is rated Sell by MarketsMOJO, with this rating last updated on 07 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Procter & Gamble Health Ltd has reached a new 52-week low today, with its stock price touching Rs.4781. This marks a significant decline amid broader market weakness and ongoing challenges within the Pharmaceuticals & Biotechnology sector.

Procter & Gamble Health Ltd has reached a new 52-week low of Rs.4824.05, marking a significant decline in its stock price amid broader market movements and sectoral pressures. The stock has underperformed its sector and key indices, reflecting a combination of subdued financial results and valuation concerns.

Procter & Gamble Health Ltd is rated Sell by MarketsMOJO. This rating was last updated on 07 Jan 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 04 March 2026, providing investors with the latest perspective on the company’s position.

Procter & Gamble Health Ltd’s share price declined to a fresh 52-week low of Rs.4845.15 today, marking a significant milestone in the stock’s recent performance. Despite a slight rebound after two consecutive days of falls, the stock remains below all key moving averages, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Procter & Gamble Health Ltd’s stock reached a fresh 52-week low of Rs.4872 today, marking a significant decline amid broader market weakness and company-specific performance factors. The stock has underperformed its sector and key benchmarks, reflecting a challenging period for the pharmaceuticals and biotechnology company.

Procter & Gamble Health Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 21 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Procter & Gamble Health Ltd is rated Sell by MarketsMOJO, with this rating last updated on 07 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Procter & Gamble Health Ltd. reported a mixed performance for Q3 FY26 (October-December 2025), with net profit declining 12.37% quarter-on-quarter to ₹77.59 crores despite revenue growth of 15.06%. The pharma major, with a market capitalisation of ₹8,602 crores, continues to trade at premium valuations even as operational challenges persist. The stock has declined 13.27% over the past three months and currently trades at ₹5,193.95, down 1.24% from the previous close.

Procter & Gamble Health Ltd is rated Sell by MarketsMOJO, with this rating last updated on 07 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 30 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Procter & Gamble Health Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 January 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

Procter & Gamble Health Ltd has seen its investment rating downgraded from Hold to Sell as of 7 January 2026, driven primarily by a deterioration in technical indicators and valuation metrics. Despite a solid long-term return relative to the Sensex, the company’s flat recent financial performance and expensive valuation have raised concerns among analysts, prompting a reassessment of its investment appeal.

Procter & Gamble Health Ltd (P&G Health) has experienced a subtle shift in its technical momentum, moving from a mildly bullish to a mildly bearish trend as of early January 2026. Despite a strong long-term performance relative to the Sensex, recent technical indicators suggest caution for investors as mixed signals emerge from key momentum and trend-following tools.

Procter & Gamble Health Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development suggests a potential shift towards a bearish trend, reflecting a deterioration in the stock’s medium-term momentum and raising concerns about long-term weakness in the Pharmaceuticals & Biotechnology sector player.

Procter & Gamble Health Ltd is rated Hold by MarketsMOJO, with this rating last updated on 06 Oct 2025. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 29 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

P & G Health Ltd has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor perception. This adjustment comes amid a backdrop of mixed financial trends and valuation considerations within the Pharmaceuticals & Biotechnology sector.